Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,111 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Granulocyte colony stimulating factor (GCSF) Clear all
Completed Phase 2 Interventional Results available

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

NCT00499343
View directory record Official record
Conditions
Lymphoma
Interventions
Etoposide, G-CSF, GM-CSF, Isophosphamide, Rituximab, Apheresis
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

NCT00569673
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, pegfilgrastim, docetaxel, trabectedin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
37
States / cities
Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 7, 2026, 10:48 AM EDT
Terminated Phase 2 Interventional

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

NCT05780879
View directory record Official record
Conditions
Secondary Acute Myeloid Leukemia
Interventions
Venetoclax, FLAG or CLAG Protocol
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

NCT00009880
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 7, 2026, 10:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

NCT00503880
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
filgrastim, clofarabine, cytarabine, microarray analysis, biopsy
Biological · Drug · Genetic + 1 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 7, 2026, 10:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

NCT03077542
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
haploidentical stem cell transplant, Sirolimus, Alemtuzumab, Pentostatin, Cyclophosphamide, Hydroxyurea, Filgrastim
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional

Tumor Cell Vaccine in Treating Patients With Advanced Cancer

NCT00002505
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, recombinant interferon gamma, tumor cell lysate vaccine therapy
Biological
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2006
U.S. locations
4
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

NCT00385788
View directory record Official record
Conditions
Hodgkin's Disease
Interventions
Gemcitabine, Fludarabine, Melphalan, Antithymocyte Globulin, Allogeneic Stem Cell Infusion, Tacrolimus, Filgrastim (G-CSF), Methotrexate
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

NCT00003042
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, melphalan, mesna, paclitaxel, tamoxifen citrate, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 7, 2026, 10:48 AM EDT
Completed No phase listed Observational

National Marrow Donor Program Long-Term Donor Follow-Up

NCT01362179
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 60 Years
Enrollment
21,974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
28
States / cities
Duarte, California • Oakland, California • Santa Ana, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

NCT00002596
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
bleomycin sulfate, filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older · Male only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
149
States / cities
Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 7, 2026, 10:48 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

NCT00515138
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

NCT00349778
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

NCT00185640
View directory record Official record
Conditions
Blood Cancer, Leukemia
Interventions
Cyclosporine, Anti-thymocyte globulin (ATG), Mycophenolate mofetil (MMF), Filgrastim, Total Lymphoid Irradiation (TLI)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 70 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional

Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma

NCT00008268
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 7, 2026, 10:48 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

NCT03560752
View directory record Official record
Conditions
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 3 Interventional

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

NCT00003128
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
17
States / cities
Birmingham, Alabama • Stanford, California • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Scleroderma Treatment With Autologous Transplant (STAT) Study

NCT01413100
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Plerixafor, Quality-of-Life Assessment, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 7, 2026, 10:48 AM EDT
Not yet recruiting Phase 2 Interventional

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

NCT07059611
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
RP2, 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Pegfilgrastim, Filgrastim, Surgical Resection of Primary Tumor
Biological · Combination Product · Drug + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer

NCT00004087
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

NCT00002552
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, sargramostim, carmustine, cyclophosphamide, cytarabine, etoposide, leucovorin calcium, methotrexate, perfosfamide, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2003
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

NCT00580034
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
Interventions
Campath Purged Non-myeloablative ASCT, Donor Apheresis
Drug · Procedure
Lead sponsor
David Rizzieri, MD
Other
Eligibility
17 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 1 Interventional

Total Marrow Irradiation for Refractory Acute Leukemia

NCT00686556
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Interventions
cyclophosphamide, cyclosporine, Fludarabine, mycophenolate mofetil, total marrow irradiation, umbilical cord blood transplantation, Granulocyte colony-stimulating factor, HLA-matched related donor bone marrow
Drug · Radiation · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 7, 2026, 10:48 AM EDT
Withdrawn Phase 2 Interventional

Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers

NCT02682953
View directory record Official record
Conditions
Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma, Lymphoma
Interventions
Neupogen, Hyperbaric oxygen therapy, Plerixafor
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 7, 2026, 10:48 AM EDT